Hi Stef2011,
You mentioned spending money on real treatments like rep9ac..
Any news about this agent?
Thanks.
keep inmind that pegintf patent is also about to expire so they are mixing with new interferons but if hbsag clearance is the same is just a way to rip off money.it is much better to spend our own money for real treatments like rep9ac at this point and get replicor to do it or another lab to copy it where it is legal and patents have no validity
normal intf is generic from long time but i haven t seen it on western markets only asia
http://www.isvhld2012.org/program.html. Here i saw the abstracts
I can only see papers on
1. Mycrludex by Prof Stephen Urban
2. REP9AC by Dr Andrew Vaillant
3. A molecule to disrupt cccDNA formation by Dr HT Guo
4. Interferon XL by Dr Trepo
Really very sad. Gave a glimpse to the abstracts of International Symposium of Viral Hepatitis that will be held in china on 22 June and was surprised by the vast number of abstracts concerning HBV. Hope for the best...
I read researchers in Lyon is trialling (HepC) an extended release Interferon XL.. In Singapore, researchers have developed compound to deliver Interferon alpha to HBV infected liver cells using T-cell receptor like antibodies. All these ideas and no new treatment in sight. Very frustrating.
http://www.prnewswire.com/news-releases/roche-and-maxygen-establish-broad-alliance-to-develop-and-commercialize-next-generation-interferon-alpha-and-beta-products-55732947.html